about
Cyclin-dependent kinase 5 activity is required for T cell activation and induction of experimental autoimmune encephalomyelitisCyclin-dependent kinase 5 modulates nociceptive signaling through direct phosphorylation of transient receptor potential vanilloid 1Roscovitine in cancer and other diseasesMolecular basis of differential selectivity of cyclobutyl-substituted imidazole inhibitors against CDKs: insights for rational drug designRSK2 Binding Models Delineate Key Features for ActivityA high throughput, whole cell screen for small molecule inhibitors of the mitotic spindle checkpoint identifies OM137, a novel Aurora kinase inhibitorRoscovitine inhibits EBNA1 serine 393 phosphorylation, nuclear localization, transcription, and episome maintenanceKinase inhibitor scaffolds against neurodegenerative diseases from a Southern Australian ascidian, Didemnum sp.Discovery of thienoquinolone derivatives as selective and ATP non-competitive CDK5/p25 inhibitors by structure-based virtual screeningNiemann-Pick type C pathogenesis and treatment: from statins to sugars.Selectivity and potency of cyclin-dependent kinase inhibitors.Structure-activity relationship study of 2,4-diaminothiazoles as Cdk5/p25 kinase inhibitors.Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders.Protein kinase-inhibitor database: structural variability of and inhibitor interactions with the protein kinase P-loop.Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis.Protein kinases in organ ischemia and reperfusion.Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period.Structural basis for the different stability and activity between the Cdk5 complexes with p35 and p39 activators.Inhibition of CDKS by roscovitine suppressed LPS-induced *NO production through inhibiting NFkappaB activation and BH4 biosynthesis in macrophagesComputational study of the inhibitory mechanism of the kinase CDK5 hyperactivity by peptide p5 and derivation of a pharmacophore.The interaction of Munc 18 (p67) with the p10 domain of p35 protects in vivo Cdk5/p35 activity from inhibition by TFP5, a peptide derived from p35.Tau as a therapeutic target for Alzheimer's diseaseCyclin-dependent kinases: bridging their structure and function through computations.Kinetics, in silico docking, molecular dynamics, and MM-GBSA binding studies on prototype indirubins, KT5720, and staurosporine as phosphorylase kinase ATP-binding site inhibitors: the role of water molecules examined.Transcriptional analysis reveals distinct subtypes in amyotrophic lateral sclerosis: implications for personalized therapy.Insights into Ligand-Protein Binding from Local Mechanical Response.Structural basis of valmerins as dual inhibitors of GSK3β/CDK5.Binding Mechanism of Inhibitors to CDK5/p25 Complex: Free Energy Calculation and Ranking Aggregation Analysis.Novel genetic tools reveal Cdk5's major role in Golgi fragmentation in Alzheimer's disease.Automating crystallographic structure solution and refinement of protein-ligand complexes.Phosphorylation of cyclin-dependent kinase 5 (Cdk5) at Tyr-15 is inhibited by Cdk5 activators and does not contribute to the activation of Cdk5.Structural and dynamic determinants of ligand binding and regulation of cyclin-dependent kinase 5 by pathological activator p25 and inhibitory peptide CIP.Structural features underlying selective inhibition of GSK3β by dibromocantharelline: implications for rational drug design.Docking and 3D-QSAR modeling of cyclin-dependent kinase 5/p25 inhibitors.Different mechanisms of CDK5 and CDK2 activation as revealed by CDK5/p25 and CDK2/cyclin A dynamics.Epigenetic modulation of Cdk5 contributes to memory deficiency induced by amyloid fibrils.Molecular dynamic simulations give insight into the mechanism of binding between 2-aminothiazole inhibitors and CDK5.Studying the mechanism that enables paullones to selectively inhibit glycogen synthase kinase 3 rather than cyclin-dependent kinase 5 by molecular dynamics simulations and free-energy calculations.Investigation of the flexibility of protein kinases implicated in the pathology of Alzheimer's disease.
P2860
Q24623805-51ABFD55-BA6D-4414-9A47-FE5A00D9E237Q24675401-8CBECC3A-A967-4FBC-98AE-F4A4998D4B04Q26799874-977024CD-70AD-4A3A-8CC4-5E742CDF088AQ28533443-DFAFDC62-AAA5-4155-833E-B58D47E74338Q30432330-667B4512-D7FA-4770-B974-42FC9271489EQ30437056-6D10C596-C864-4FAA-9564-64E8BD2E5AB4Q33786506-C637618B-3B92-4FDA-AB22-F2C74239FDCFQ34244752-67DD4777-5003-432B-92EF-9D699D3168B1Q34625383-49DECC7D-8AAC-480E-B1AD-A7574A752864Q34632493-C915B112-FED3-46E8-9742-EF44BB3E2225Q34651981-D90CED93-9E7A-4D2F-8D3C-0DFBD88A762CQ34706737-DADCB2A5-45D5-42EC-AAD9-FA5A03A8B8A6Q34914245-1EDBB944-E404-4F12-A148-E9C36F5E9F73Q35606325-4E8CA220-D662-4B48-9BD7-F01011B0C03AQ36709312-212E4CB8-66A5-493C-A688-E71169EFB65EQ37211896-B1588CE3-A4CA-43FE-9C34-60BF1B3D0385Q37280604-0B0CDFEA-2B53-420A-BDF9-EC936246869EQ37289231-3A0EE947-6532-481D-A1FB-AC332AD15F3FQ37338910-5BE3D87F-482E-4DD3-AE70-154DA86A02D9Q37503295-0EE7E7B6-5118-41FF-B895-A897653E0140Q37518226-69F21874-628B-472C-B849-F9F0A3EBA9FDQ37890451-D23E7095-7045-4F2C-82DD-B52A1EDA06BAQ37924806-EB51519B-5511-438C-A14B-C654EF211340Q38337597-5FED4172-F5F3-4764-BC29-3DECE0104448Q38542939-86DF973C-4791-491D-983A-05FACFD87947Q38684570-0DEC102A-667B-4DEF-92C4-85FE53BD73FEQ39142231-8E9C784B-B0AA-4EB0-B2FA-FBB3016C080AQ39460467-3FFA6C82-AE49-4A19-82EB-78DDA9FDB4FAQ39630367-4AD0001F-AA01-42F0-80E6-7B89B21D4F36Q41940007-B65BDC0B-F353-4BA3-8184-F1E969A22D8AQ41968676-94694A63-C781-43D7-BF81-E135BFF4843BQ42549261-02E187C1-52DD-4AB2-9D4C-C39185293965Q43986703-68200658-102F-4179-ABC6-A94520F42CCEQ44045827-7EFAFC99-2A5D-4E24-964C-66A90751601AQ46890342-EC2E5068-B023-4444-8A90-F75D8B741998Q48532158-45348F84-A123-4A42-B4B7-0E012DA33E9DQ54441914-A412BB54-74C0-4FEA-8FBD-3C7F538A4CD9Q54667185-C3B16DF2-3196-4CF6-AE0E-34B0C55ECAE8Q55073370-21150941-1282-43CA-9EB4-0B6733F1D387
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Mechanism of CDK5/p25 binding by CDK inhibitors
@ast
Mechanism of CDK5/p25 binding by CDK inhibitors
@en
Mechanism of CDK5/p25 binding by CDK inhibitors
@en-gb
Mechanism of CDK5/p25 binding by CDK inhibitors
@nl
type
label
Mechanism of CDK5/p25 binding by CDK inhibitors
@ast
Mechanism of CDK5/p25 binding by CDK inhibitors
@en
Mechanism of CDK5/p25 binding by CDK inhibitors
@en-gb
Mechanism of CDK5/p25 binding by CDK inhibitors
@nl
prefLabel
Mechanism of CDK5/p25 binding by CDK inhibitors
@ast
Mechanism of CDK5/p25 binding by CDK inhibitors
@en
Mechanism of CDK5/p25 binding by CDK inhibitors
@en-gb
Mechanism of CDK5/p25 binding by CDK inhibitors
@nl
P2093
P356
P1476
Mechanism of CDK5/p25 binding by CDK inhibitors
@en
P2093
Claudia Crovace
Laurent Meijer
Li-Huei Tsai
Lucia Massimiliano
Marina Mapelli
P356
10.1021/JM049323M
P407
P577
2005-02-10T00:00:00Z